GENE THERAPY METHODS FOR ARRHYTHMOGENIC CARDIOMYOPATHY

The present disclosure provides methods of treating an arrhythmogenic cardiomyopathy (ACM) in a subject. The methods generally comprise administering to the subject a gene therapy comprising a first nucleic acid encoding soluble transforming growth factor beta receptor 2 (sTGFbR2) and a second nucle...

Full description

Saved in:
Bibliographic Details
Main Authors OLIVER, Dan, DAVIDSOHN, Noah
Format Patent
LanguageEnglish
French
Published 28.03.2024
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides methods of treating an arrhythmogenic cardiomyopathy (ACM) in a subject. The methods generally comprise administering to the subject a gene therapy comprising a first nucleic acid encoding soluble transforming growth factor beta receptor 2 (sTGFbR2) and a second nucleic acid encoding fibroblast growth factor 21 (FGF21). La présente invention concerne des méthodes de traitement d'une cardiomyopathie arythmogène (ACM) chez un sujet. Les procédés comprennent généralement l'administration au sujet d'une thérapie génique comprenant un premier acide nucléique codant pour le récepteur 2 du facteur de croissance transformant bêta soluble (sTGFbR2) et un second acide nucléique codant pour le facteur de croissance des fibroblastes 21 (FGF21).
Bibliography:Application Number: WO2023US74747